Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

NCT03060980 on ClinicalTrials.gov · last registry update 2019-03-07

Stopped early, having planned 245 participants. The sponsor logged completion for 26 January 2018. Primary outcome, as filed: Reduction in glycosylated hemoglobin A1c. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Intarcia Therapeutics
Sponsor type: Industry
Enrollment: 245
Started: 2017-03-03
Primary completion: 2018-01-26 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Reduction in glycosylated hemoglobin A1c

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.